STAT3 and neoplasm: In conclusion, the findings from our studies suggest that the tyrosine kinase inhibitor sorafenib exhibits anti-tumor activity on its own through the inhibition of proliferation and the induction of apoptosis via inhibition of the ERK/MAPK and STAT3 pathways in OSA cells.